• Wed. May 29th, 2024

New Breakthrough Drug Brings Hope to Patients with Pulmonary Embolism: Sotatracept Reduces Risk of Worsening Events by 84%

BySamantha Jones

Mar 28, 2024
Groundbreaking Medical News Impacts Millions of Patients Globally

Pulmonary embolism is a disease that primarily affects young people, particularly women, with the peak incidence occurring between the ages of 30-40. However, it can also occur at later ages. Patients with pulmonary embolism are categorized based on function levels and risk levels, ranging from 1 (highest function) to 4 (lowest function).

For a decade, there were no advancements in the treatment of pulmonary embolism, with existing treatments mainly focused on alleviating symptoms. This has now changed with the American Food and Drug Administration (FDA) recently approving a groundbreaking drug called sotatracept. Sotatracept is the first of its kind to treat the disease itself, rather than just symptoms.

Sotatracept works by inhibiting a unique component called “activin,” which changes the mechanism of the cells that drive the disease. This approval marks a significant improvement for patients with pulmonary hypertension, offering better survival rates, delaying disease progression, and reducing the risk of worsening events or death by approximately 84%.

According to Prof. Mordechai Kramer, director of the pulmonary department at Blinson Hospital, pulmonary hypertension is a serious and life-threatening disease. The Ministry of Health usually approves drugs that have been approved by the FDA after reviewing research findings submitted by companies. With this approval, sotatracept provides new hope for patients who have not responded well to existing treatments.

By Samantha Jones

As a content writer at newsnnk.com, I weave words into captivating stories that inform and engage our readers. With a passion for storytelling and an eye for detail, I strive to deliver high-quality and engaging content that resonates with our audience. From breaking news to thought-provoking features, I am dedicated to providing informative and compelling articles that keep our readers informed and entertained. Join me on this journey as we explore the world through the power of words.

Leave a Reply